ZVIAZevia PBC
The Read
6 million year-over-year despite meeting EPS estimates, then rebounded about 5.
The schedule
- Thu15Oct
A large incumbent beverage competitor is expected to expand its zero-sugar portfolio with a national marketing push, intensifying shelf and promotional pressure in Zevia’s core categories.
- Fri15Jan
Potential strategic review or acquisition speculation as larger beverage players or financial sponsors reassess Zevia’s brand value, distribution footprint, and public-market micro-cap discount.
- Wed3Feb
Q3 2026 earnings and initial 2027 commentary will indicate whether Zevia can withstand intensifying competition while sustaining revenue growth and progressing toward full-year profitability targets.
- Sun14Feb
Full-year 2026 results and Q4 performance will show whether Zevia has turned the corner on consistent cash generation and margin expansion after a year of competitive and strategic developments.
- Wed5May
Q1 2027 earnings will test whether any late-2026 improvements in growth, margins, or strategic positioning are durable as Zevia enters a new fiscal year.
Past
- Wed5Aug
Q2 2026 earnings update on whether Zevia can sustain >20% revenue growth while moving closer to consistent profitability and cash-flow break-even under the new packaging strategy.
- Sat25Jul
Actual outcome: Bull · $1.65 at outcome
Stock rose 9.7% from event to outcome date, aligning with the bull trajectory.
Market evaluation of ZVIA's cash runway from a base of $1.77, with an upside target of $1.88 if non-dilutive, and a downside risk of $1.58 on unexpected equity raises.
- Wed6May
Actual outcome: Bull · $1.21 at outcome
Zevia delivered strong Q1 2026 results, highlighted by a 21.2% year-over-year increase in net sales to $46.1 million and break-even earnings per share that topped consensus estimates. This robust top-line growth and improved bottom-line performance signaled successful execution of the company's roadmap and stabilized demand, driving the stock higher to reach the bull target.
Q1 2026 earnings at a $1.10 base price will test whether Zevia can stabilize volumes and margins after missing its own Q4 2025 revenue guidance. Delivery against its 2026 roadmap could support a rebound toward $1.22, while another miss or weak guidance would likely take the stock down toward $1.22.
- Fri10Apr
Actual outcome: Bull · $1.25 at outcome
Initial retail feedback confirmed that the packaging refresh successfully improved shelf visibility without causing distribution friction, yet early velocity data showed only modest improvements in consumer trial. This balanced outcome prevented a breakdown toward the bear floor but lacked the aggressive reorder signals necessary to trigger a move toward the bull target.
Validation of Zevia’s Q1 2026 packaging refresh and initial retailer feedback around shelf visibility, consumer trial, and any early reorder signals at a $1.18 base price. A positive read-through would support a move toward $1.26, while evidence of disruption or weak uptake could push shares down toward $1.26.
- Wed25Feb
Actual outcome: Bear · $1.43 at outcome
Zevia reported Q4 2025 net sales of $37.9 million, representing a $1.6 million year-over-year decline, while EPS of -$0.02 met analyst estimates. Despite meeting bottom-line expectations, the contraction in net sales disappointed investors and signaled ongoing top-line struggles, driving the stock down 7.7% and well below the bear floor.
Release of Q4 results and forward guidance. Critical focus on meeting or beating the Q4 net sales ($39M-$41M) and Adjusted EBITDA guidance (-$0.75M to -$0.25M), and providing a clear, credible roadmap toward sustained 2026 profitability, as previously stated by management.
